What happened
IL Dong Pharmaceutical filed provisional (unaudited) consolidated results for Q4 2025: revenue of US$101M (−5.6% year on year), operating profit of US$5.45M (−5.7% year on year) and net income of US$3.87M (+97.1% year on year).
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$101M |
|---|---|
| Revenue vs a year earlier | −5.6% |
| Operating profit | US$5.45M |
| Net income | US$3.87M |
| Period | Q4 2025 (consolidated) |
| Filed | 2026-02-11, Operating results (consolidated) (preliminary) (fair disclosure) |
| Source | DART rcept 20260211801578 → open original filing |
Source: DART. Information only, not investment advice.